🟢 Novo Nordisk is trading 3% up today as it rebounds from recent GLP-1 pricing concerns

Novo Nordisk is trading 3% up at $50.55, rebounding from recent weakness tied to GLP-1 pricing and reimbursement worries.

• The move comes despite a warning from CVS Health’s CEO that broad insurance coverage for weight-loss drugs like Wegovy remains economically challenging for employers.
• The stock appears to be recovering amid a generally positive market tape after prior selloffs driven by U.S. pricing and competition fears.